デフォルト表紙
市場調査レポート
商品コード
1608706

遺伝性血管性浮腫市場:種類別、薬剤クラス別、投与経路別、流通チャネル別、地域別

Hereditary Angioedema Market By Type, By Drug Class, By Route of Administration, By Distribution Channel, By Geography


出版日
ページ情報
英文 175 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.81円
遺伝性血管性浮腫市場:種類別、薬剤クラス別、投与経路別、流通チャネル別、地域別
出版日: 2024年11月05日
発行: Coherent Market Insights
ページ情報: 英文 175 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

遺伝性血管性浮腫市場は、2024年には28億6,000万米ドルと推定され、2031年には53億6,000万米ドルに達すると予測され、2024年から2031年までのCAGRは9.4%です。

レポート範囲 レポート詳細
基準年 2023年 市場規模 (2024年) 28億6,000万米ドル
実績データ 2019~2023年 予測期間 2024~2031年
予測期間のCAGR (2024~2031年): 9.40% 予測金額 (2031年)
図:遺伝性血管性浮腫の市場シェア (%)、地域別、2024年
Hereditary Angioedema Market-IMG1

遺伝性血管性浮腫は、激しい皮下または粘膜下浮腫の再発を特徴とするまれな遺伝性疾患です。症状には、手、足、四肢、顔、腸管および気道の腫脹のエピソードが含まれます。このエピソードは、補体および線溶系の特定の部分を制御する血清蛋白であるC1インヒビターの濃度低下または機能低下によって引き起こされます。遺伝性血管性浮腫の患者は、平均して少なくとも4週間に1回浮腫のエピソードを経験し、一般的に症状管理のために医学的介入を必要とします。この疾患の世界の有病率の増加と、利用可能な治療オプションに関する意識の高まりが、遺伝性血管性浮腫市場の成長を促進する可能性があります。

市場力学

代替治療法の研究の増加、世界のHAEの有病率の上昇、FDA承認薬の入手可能性、病気に対する意識の高まりが、遺伝性血管性浮腫市場の成長を促進する可能性があります。しかし、HAE治療に伴う高額な費用や新興国市場における認知度の低さが、市場開拓の妨げになる可能性があります。皮下C1-INH製品や経口治療薬の開拓は、市場プレイヤーに新たな機会を提供します。

本調査の主な特徴

当レポートでは、世界の遺伝性血管性浮腫市場を詳細に分析し、2023年を基準年とした予測期間 (2024-2031年) の市場規模および複合年間成長率 (CAGR%) を掲載しています。

また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。

また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。

世界の遺伝性血管性浮腫市場における主要な企業について、企業ハイライト、製品ポートフォリオ、主要なハイライト、業績、戦略などのパラメータに基づいてプロファイルしています。

主な企業は、CSLベーリング、サノフィ、武田薬品工業、Orchard Therapeutics plc.、Pharming Group N.V.、BioCryst Pharmaceuticals, Inc.、Ionis Pharmaceuticals, Inc.、Attune Pharmaceuticals、Arrowhead Pharmaceuticals, Inc.、Adverum Biotechnologies, Inc.、KalVista Pharmaceuticals、CENTOGENE N.V.などです。

当レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。

世界の遺伝性血管性浮腫市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。

利害関係者は、世界の遺伝性血管性浮腫市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 分析目的と前提条件

  • 分析目的
  • 前提条件
  • 略語

第2章 市場の展望

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー

第3章 市場力学・規制・動向の分析

  • 市場力学
  • 影響分析
  • 主なハイライト
  • 規制シナリオ
  • 製品の発売/承認
  • PEST分析
  • Porterの分析
  • 企業合併・買収 (M&A) のシナリオ
  • 疫学

第4章 遺伝性血管性浮腫市場:種類別、2019~2031年 (10億米ドル)

  • 遺伝性血管性浮腫I型
  • 遺伝性血管性浮腫II型

第5章 遺伝性血管性浮腫市場:薬剤クラス別、2019~2031年 (10億米ドル)

  • C1エステラーゼ阻害剤
  • カリクレイン阻害剤
  • ブラジキニン受容体
  • 弱毒化アンドロゲン
  • その他

第6章 遺伝性血管性浮腫市場:投与経路別、2019~2031年 (10億米ドル)

  • 皮下
  • 経口

第7章 遺伝性血管性浮腫市場:流通チャネル別、2019~2031年 (10億米ドル)

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 遺伝性血管性浮腫市場:地域別、2019~2031年 (10億米ドル)

  • 北米
  • ラテンアメリカ
  • 欧州
  • アジア太平洋
  • 中東
  • アフリカ

第9章 競合情勢

  • CSL Behring
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Orchard Therapeutics plc.
  • Pharming Group N.V.
  • BioCryst Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Attune Pharmaceuticals
  • Arrowhead Pharmaceuticals, Inc.
  • Adverum Biotechnologies, Inc.
  • KalVista Pharmaceuticals
  • CENTOGENE N.V.

第10章 アナリストの推奨事項

  • 運命の輪
  • アナリストの見解
  • 一貫した機会マップ

第11章 参考文献と調査手法

  • 参考文献
  • 調査手法
  • 出版社について
目次
Product Code: CMI1292

Hereditary angioedema market is estimated to be valued at USD 2.86 Bn in 2024 and is expected to reach USD 5.36 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.4% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: 2.86 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 9.40% 2031 Value Projection: 5.36 Bn
Figure. Hereditary Angioedema Market Share (%), By Region, 2024
Hereditary Angioedema Market - IMG1

Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of intense subcutaneous or submucosal edema. Symptoms include episodes of swelling in the hands, feet, limbs, face, intestinal tract and airway. The episodes are caused by decreased levels or functioning of C1 inhibitor, which is a serum protein responsible for regulating certain parts of the complement and fibrinolytic systems. Patients with hereditary angioedema experience episodes of edema at least once every 4 weeks on average and commonly require medical intervention for symptom management. Increasing prevalence of disease globally and rising awareness about available treatment options can drive the hereditary angioedema market growth.

Market Dynamics

Increasing research into treatment alternatives, rising prevalence of HAE globally, availability of FDA approved drugs and growing awareness about the disease can drive the hereditary angioedema market growth. However, high costs associated with HAE therapies and lack of awareness in developing countries can hamper the market growth. Development of subcutaneous C1-INH products and oral treatments offers new opportunities for the market players.

Key features of the study

This report provides in-depth analysis of the global hereditary angioedema market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global hereditary angioedema market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include CSL Behring, Sanofi, Takeda Pharmaceutical Company Limited, Orchard Therapeutics plc., Pharming Group N.V., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, and CENTOGENE N.V.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hereditary angioedema market

Market Segmentation

  • By Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Hereditary Angioedema Type I
    • Hereditary Angioedema Type II
  • By Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
    • C1 Esterase Inhibitor
    • Kallikrein Inhibitor
    • Bradykinin Receptor
    • Attenuated Androgens
    • Others
  • By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
    • Subcutaneous
    • Intravenous
    • Oral
  • By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • CSL Behring
    • Sanofi
    • Takeda Pharmaceutical Company Limited
    • Orchard Therapeutics plc.
    • Pharming Group N.V.
    • BioCryst Pharmaceuticals, Inc.
    • Ionis Pharmaceuticals, Inc.
    • Attune Pharmaceuticals
    • Arrowhead Pharmaceuticals, Inc.
    • Adverum Biotechnologies, Inc.
    • KalVista Pharmaceuticals
    • CENTOGENE N.V.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Hereditary Angioedema Market, By Type
    • Hereditary Angioedema Market, By Drug Class
    • Hereditary Angioedema Market, By Route of Administration
    • Hereditary Angioedema Market, By Distribution Channel
    • Hereditary Angioedema Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Epidemiology
  • Pipeline Analysis

4. Hereditary Angioedema Market, By Type, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hereditary Angioedema Type I
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Hereditary Angioedema Type II
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Hereditary Angioedema Market, By Drug Class, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • C1 Esterase Inhibitor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Kallikrein Inhibitor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Bradykinin Receptor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Attenuated Androgens
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Hereditary Angioedema Market, By Route of Administration, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Subcutaneous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    • Intravenous
  • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Hereditary Angioedema Market, By Distribution Channel, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Hereditary Angioedema Market, By Region, 2019 - 2031, (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

9. Competitive Landscape

  • CSL Behring
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical Company Limited
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Orchard Therapeutics plc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pharming Group N.V.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • BioCryst Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Ionis Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Attune Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Arrowhead Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Adverum Biotechnologies, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • KalVista Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • CENTOGENE N.V.

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us